TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Mitral Mysteries: Imagers Explore a New Frontier in Transcatheter Valve Replacement

Transcatheter aortic valve replacement offers valuable lessons that can be applied to its mitral valve counterpart, according to imagers on the frontlines for both techniques.

Thumbnail

Same-day discharge for TAVR marks new procedural milestone

One morning last year, a patient checked into a hospital in Canada as the first TAVR case of the day, and they were discharge by that evening. It was an eyebrow-raising feat for a procedure that typically requires several days of hospitalization.

TAVR in low-risk patients holds steady at 2 years

Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery in low-risk patients with severe aortic stenosis, based on two-year results presented May 19 at EuroPCR in Paris.

Boston Scientific receives CE Mark for the new 25 mm Lotus Valve System

Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes.

Boston Scientific Lotus Valve System demonstrates strong performance and safety profile at six months

Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation Lotus Valve System continued to demonstrate impressive performance at six months, according to new data presented at EuroPCR 2014 in Paris.

Medtronic CoreValve System demonstrates positive clinical performance at two years in 'real world' ADVANCE study

Medtronic, Inc. today revealed new data showing that patients treated with the CoreValve System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates of mortality and stroke, and showed exceptional valve performance through two years.

Henry Ford Hospital pioneers new cardiac approach

Doctors at Henry Ford Hospital have created a new route to the heart to implant an artificial heart valve by temporarily connecting major blood vessels that do not normally intersect.

EuroPCR: SOURCE Registry one-year mortality rates inform TAVI operators

Martyn Thomas, MD, director of cardiothoracic services, Guys and St. Thomas' NHS Foundation Trust in London, reported Tuesday on the one-year mortality rates with transcatheter heart valve implantations with the Sapien valve (Edwards Lifesciences) using either a transfemoral or transapical approach, based on results of 1,038 high-risk patients assessed in the SOURCE Registry at EuroPCR in Paris. Slides

Displaying 401 - 408 of 408

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup